TVGN

WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) announced that its 2026 Annual Meeting of Stockholders (the "Annual Meeting)" is scheduled for Monday, August 24, 2026. The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof. Because the meeting date is more than 30 days after the one-year anniversary date of the 2025 Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934 (the "Exchange Act") for consideration at the Annual Meeting must be receive

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

S-8 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

EFFECT - Tevogen Bio Holdings Inc. (0001860871) (Filer)

S-3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader, revenue-generating healthcare enterprise. The initiative will be led on an interim basis by William Keane, Tevogen's Vice President of Strategic Initiatives. The healthcare services initiative may include, if consummated, the Company's currently evaluated acquisition oppo

WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company's previously announced evaluation of a contract research organization ("CRO"), along with additional strategic acquisition opportunities aligned with Tevogen's broader healthcare platform. Tevogen believes these and other strategic acquisition initiatives could support the Compan

WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to evaluate a potential transaction with a Management Services Organization ("MSO"). If consummated, the proposed transaction could expand Tevogen's healthcare infrastructure capabilities and support the Company's evolution into a revenue-generating healthcare enterprise comprised of Tevogen Bio, its biotechnology arm; Tevogen.AI, its technology arm; and, subject to completion of proposed transactions, a healthcare services arm that may include management services and contract r

WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital. We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss from operations decreasing to $5.4 million, a 48% improvement compared to the same period in

10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the "PIPE") financing with existing investor The Patel Family, LLP for gross proceeds of $3 million. The Company intends to use the proceeds from the PIPE financing to support ongoing operations, advance strategic growth initiatives, and for general corporate purposes. Pursuant to the terms of the securities purchase agreement, Tevogen will issue 375,000 prefunded warrants each exercisable for the purchase of one share of the Company's common stock. The PIPE financ

10-K/A - Tevogen Bio Holdings Inc. (0001860871) (Filer)

WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness. PredicTcell™, Tevogen.AI's proprietary machine learning model designed to identify immunologically active peptides, is approaching the final stages of its training phase. The model has been trained on one of the industry's largest curated peptide datasets, with feature expansion now exceeding 180 parameters, contributing to an approximate 10% improvement in precision. As

8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

10-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries, providing global clinical development capabilities WARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices. If completed, the transaction would represent a meaningful step in Tevogen's evolution toward a

424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)